InsiderTrades

Form 4 for ORMP ORAMED PHARMACEUTICALS INC.

Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-03 · accession 0001213900-22-000818 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-01-05 2022-01-03 ORMP KIDRON NADAV Pres, CEO, Dir A - Grant — +213.0K 936.5K +29% —
D 2022-01-05 2022-01-03 ORMP KIDRON NADAV Pres, CEO, Dir F - Tax $13.89 -48.8K 887.7K -5% -$677.2K
D 2022-01-05 2022-01-03 ORMP KIDRON NADAV Pres, CEO, Dir A - Grant $0.00 +107.0K 107.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-01-03 A A 63,000 — 950,729 D — — (F3) Represents Restricted Stock Units ("RSUs") that will vest in 4 installments as follows: 15,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.
2 Common Common Stock 2022-01-03 F D 48,752 $13.89 887,729 D — — (F2) Payment of tax liability by withholding securities incident to the 150,000 shares of Common Stock granted on January 3, 2022.
3 Common Common Stock 2022-01-03 A A 150,000 — 936,481 D — — (F1) Represents Common Stock granted by the Issuer that vested upon grant.
4 Derivative Stock Option (right to buy 2022-01-03 A A 107,000 $0.00 107,000 D $13.89 · — to 2032-01-03 107,000 Common Stock (F4) The Stock Option will vest in 4 installments as follows: 26,750 shall vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026.